Margaret Chu-Moyer, PhD, joined Amgen in 2009. She is currently VP, Research and Head of Small Molecule Therapeutic Discovery (SMTD). Her team is responsible for advancing Amgen’s small molecule portfolio, from the very early stages of hit identification through the hit-to-lead and lead optimization phases, to the later stages of candidate selection and qualification. These small molecule pre-clinical candidates are the foundation of novel therapeutics to treat serious diseases.
Working in partnership with Amgen’s Research therapeutic areas, including cardiometabolic diseases, inflammation and oncology, a number of molecules have advanced through the clinic, including AMG 510/sotorasib, now known as LUMAKRAS™/LUMYKRAS™, which was approved in 2021 as the first targeted therapy directed at KRAS G12C-mutant tumors for the treatment of advanced non-small cell lung cancer. The SMTD team is also intently investigating induced proximity as the newest small molecule modality to address previously “undruggable” proteins.
Previously, Margaret also held the role of Site Head for Amgen’s Cambridge, MA research facility from 2010 to 2014. Prior to joining Amgen, Margaret led both Medicinal Chemistry and Hit-To-Lead groups at Pfizer. Margaret received her B.S. in Chemistry from the University of California, Berkeley, and a Ph.D. in Organic Chemistry from Yale University.